Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3151 |
Name | skin squamous cell carcinoma |
Definition | A skin carcinoma that has_material_basis_in squamous cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin carcinoma skin squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
HRAS Q61L | PLX7904 | skin squamous cell carcinoma | no benefit | detail... |
MAP2K1 E203K PIK3CA amp | Metformin + Trametinib | skin squamous cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02324608 | Phase I | Cetuximab | Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer | Completed | USA | 0 |
NCT02449681 | Phase II | TH-4000 | Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS | Terminated | USA | AUS | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT02760498 | Phase II | Cemiplimab | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Completed | USA | ITA | GRC | FRA | ESP | DEU | BRA | AUS | 0 |
NCT02964559 | Phase II | Pembrolizumab | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | Completed | USA | 0 |
NCT02978625 | Phase II | Nivolumab + Talimogene laherparepvec | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | Active, not recruiting | USA | 0 |
NCT03108131 | Phase II | Atezolizumab + Cobimetinib | Cobimetinib and Atezolizumab in Advanced Rare Tumors | Completed | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03284424 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) | Completed | USA | NOR | ISR | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT03524326 | Phase I | Cetuximab + Lenvatinib | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03539198 | Phase 0 | Nivolumab | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | Terminated | USA | 0 |
NCT03666325 | Phase II | Pembrolizumab Cetuximab + Pembrolizumab | Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle) | Unknown status | ITA | 0 |
NCT03767348 | Phase Ib/II | Nivolumab + RP1 RP1 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) | Recruiting | USA | GBR | FRA | ESP | DEU | 0 |
NCT03816332 | Phase I | Ipilimumab + Nivolumab + Prednisone + Tacrolimus | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | Active, not recruiting | USA | 0 |
NCT03833167 | Phase III | Pembrolizumab | Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | Active, not recruiting | USA | ROU | POL | NZL | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 6 |
NCT03871348 | Phase I | SAR441000 Cemiplimab + SAR441000 | A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Terminated | USA | NLD | FRA | ESP | DEU | BEL | 0 |
NCT03889912 | Phase I | Cemiplimab | Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03901573 | Phase Ib/II | Atezolizumab + NT-I7 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Terminated | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03944941 | Phase II | Avelumab Avelumab + Cetuximab | Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer | Active, not recruiting | USA | 0 |
NCT03969004 | Phase III | Cemiplimab | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma | Active, not recruiting | USA | POL | NZL | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 2 |
NCT04050436 | Phase II | Cemiplimab + RP1 RP1 | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) | Active, not recruiting | USA | POL | ITA | GRC | FRA | ESP | DEU | CAN | BGR | AUS | 0 |
NCT04105543 | Phase I | CLR 131 | CLR 131 Combined With Radiation for Head and Neck Cancer | Completed | USA | 0 |
NCT04154943 | Phase II | Cemiplimab | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | Active, not recruiting | USA | DEU | AUS | 0 |
NCT04160065 | Phase I | IFx-Hu2.0 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC | Completed | USA | 0 |
NCT04163952 | Phase I | Panitumumab + Talimogene laherparepvec | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin | Active, not recruiting | USA | 0 |
NCT04204837 | Phase II | Nivolumab + Relatlimab Nivolumab | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | Recruiting | AUT | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04293679 | Phase Ib/II | Cotsiranib | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | Completed | USA | 0 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |
NCT04305795 | Phase Ib/II | ASP-1929 + Pembrolizumab ASP-1929 + Cemiplimab | An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04315701 | Phase II | Cemiplimab | A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer | Recruiting | USA | 0 |
NCT04339062 | Phase I | Cemiplimab Cemiplimab + Everolimus + Prednisone Cemiplimab + Prednisone + Sirolimus | Cemiplimab in AlloSCT/SOT Recipients With CSCC (CONTRAC) | Active, not recruiting | USA | 0 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 1 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04428671 | Phase I | Cemiplimab | Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer | Recruiting | USA | 0 |
NCT04450901 | Phase I | YBL-006 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | Active, not recruiting | AUS | 2 |
NCT04502888 | Phase I | SL-172154 | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | Terminated | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Terminated | USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | 4 |
NCT04620200 | Phase II | Ipilimumab + Nivolumab Nivolumab | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE) | Unknown status | NLD | 0 |
NCT04632433 | Phase II | Cemiplimab | Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma | Active, not recruiting | ITA | 0 |
NCT04710498 | Phase II | Atezolizumab | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Active, not recruiting | USA | 0 |
NCT04807777 | Phase II | Ruxolitinib | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT04808999 | Phase II | Pembrolizumab | Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) | Active, not recruiting | USA | 0 |
NCT04819373 | Phase II | BDB001 | BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors | Completed | USA | 0 |
NCT04913220 | Phase Ib/II | Cemiplimab + THOR-707 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUS | 1 |
NCT04916002 | Phase II | Cemiplimab + Vidutolimod | CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer | Terminated | USA | AUS | 0 |
NCT04925713 | Phase I | IFx-Hu2.0 | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer | Completed | USA | 0 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04975152 | Phase I | Cemiplimab | Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT04985825 | Phase II | Imgatuzumab | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE) | Withdrawn | 0 | |
NCT05025813 | Phase II | Pembrolizumab | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE) | Recruiting | AUS | 0 |
NCT05043714 | Phase I | NG-641 + Nivolumab | Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) | Active, not recruiting | USA | GBR | 0 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05070403 | Phase II | Afatinib | Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05076760 | Phase I | MEM-288 | Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | 0 |
NCT05085496 | Phase I | Atezolizumab | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous Squamous Cell Carcinoma | Recruiting | USA | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
NCT05220748 | Phase I | Pembrolizumab + RM-1995 RM-1995 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | Withdrawn | 0 | |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Active, not recruiting | USA | POL | ITA | HUN | FRA | ESP | CZE | BEL | 1 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05329792 | Phase II | Daromun | L19IL2/L19TNF in Skin Cancer Patients | Recruiting | ITA | FRA | ESP | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05574101 | Phase II | Cemiplimab | A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | Recruiting | USA | 0 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05729139 | Phase I | Cemiplimab + Peg-interferon alfa-2a | Cemiplimab/Peg-Interferon-a in Advanced CSCC | Withdrawn | USA | 0 |
NCT05821777 | Phase Ib/II | LB101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT05858229 | Phase Ib/II | RP1 | Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. | Recruiting | USA | 0 |
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |
NCT05878288 | Phase II | Cemiplimab | Deep sequencIng in Cutaneous Squamous CEll caRciNomas (DISCERN) | Active, not recruiting | AUS | 0 |
NCT05888844 | Phase II | INCB099280 | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Active, not recruiting | TUR | ROU | NZL | HUN | HRV | FRA | ESP | CAN | BRA | AUS | 5 |
NCT05896839 | Phase Ib/II | Ipilimumab + Nivolumab + Prednisone + Sirolimus | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | Recruiting | USA | 0 |
NCT05904496 | Phase I | BGB-30813 BGB-30813 + Tislelizumab | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ESP | AUS | 0 |
NCT05938296 | Phase I | oHSV2-PD-L1/CD3-BsAb | oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection | Recruiting | USA | 0 |
NCT06014086 | Phase I | PH-762 | Intratumoral PH-762 for Cutaneous Carcinoma | Recruiting | USA | 0 |
NCT06036836 | Phase II | Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | Recruiting | USA | TUR | NLD | ITA | FRA | DEU | CAN | AUS | 2 |
NCT06090266 | Phase Ib/II | Cemiplimab + OR502 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Recruiting | USA | 0 |
NCT06295809 | Phase II | Pembrolizumab mRNA-4157 + Pembrolizumab | A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) | Recruiting | USA | ROU | POL | NZL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 2 |
NCT06331598 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) | Recruiting | ESP | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06567314 | Phase II | Ivonescimab | Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma | Not yet recruiting | USA | 0 |
NCT06580054 | Phase II | Pembrolizumab | Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma | Not yet recruiting | USA | 0 |